According to the Zhitong Finance App, Tianda Pharmaceutical (00455.HK) announced its 2026 interim results, with revenue of about HK$164 million, up 20.19% year on year; loss attributable to the company's shareholders was HK$32.25 million, a decrease of 2.97% year on year; loss per share was HK$1.5 million.

According to the Zhitong Finance App, Tianda Pharmaceutical (00455.HK) announced its 2026 interim results, with revenue of about HK$164 million, up 20.19% year on year; loss attributable to the company's shareholders was HK$32.25 million, a decrease of 2.97% year on year; loss per share was HK$1.5 million.